IntoCell, Inc. (KOSDAQ:287840)
South Korea
· Delayed Price · Currency is KRW 39,500
-3,400 (-7.93%)
At close: Mar 9, 2026
IntoCell Revenue
IntoCell had revenue of 1.42B KRW in the quarter ending September 30, 2025, with 44.41% growth. This brings the company's revenue in the last twelve months to 1.68B, down -39.84% year-over-year. In the year 2024, IntoCell had annual revenue of 2.91B with 79.72% growth.
Revenue (ttm)
1.68B
Revenue Growth
-39.84%
P/S Ratio
352.22
Revenue / Employee
n/a
Employees
n/a
Market Cap
592.97B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HansBiomed | 100.17B |
| S.Biomedics | 16.96B |
| Y-Biologics | 3.61B |
| curacle co.,ltd. | 1.14B |
| ROKIT Healthcare | 20.33B |
| NIBEC | 32.96B |
| JS Link | 16.14B |
| Bio Solution | 8.27B |